A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910